Cargando…

Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer

OBJECTIVES: Unequivocal clinical progression (UCP)—a worsening of clinical status with or without radiographic progression (RAD)—represents a distinct mode of disease progression in metastatic prostate cancer. We evaluated the prevalence, risk factors and the impact of UCP on survival outcomes. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rao, Arpit, Scher, Howard I, De Porre, Peter, Yu, Margaret K, Londhe, Anil, Qi, Keqin, Morris, Michael J, Ryan, Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662417/ https://www.ncbi.nlm.nih.gov/pubmed/33184097 http://dx.doi.org/10.1136/esmoopen-2020-000943

Ejemplares similares

Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate Cancer
por: Anand, Aseem, et al.
Publicado: (2022)

Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)
por: Teo, Min Yuen, et al.
Publicado: (2018)

Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians
por: Sureka, Sanjoy Kumar, et al.
Publicado: (2016)

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL
por: Bryce, A H, et al.
Publicado: (2017)

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
por: Small, E J, et al.
Publicado: (2019)

Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel
por: Armstrong, Andrew J., et al.
Publicado: (2017)

Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302
por: Wilson, Brooke E., et al.
Publicado: (2022)

Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study
por: Feyerabend, Susan, et al.
Publicado: (2019)

Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Zobniw, Chrystia M, et al.
Publicado: (2014)

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
por: Devlies, Wout, et al.
Publicado: (2020)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

The cost impact of disease progression to metastatic castration-sensitive prostate cancer
por: Trinh, Quoc-Dien, et al.
Publicado: (2022)

Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry
por: Verry, Camille, et al.
Publicado: (2022)

Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
por: Lin, Ting-Ting, et al.
Publicado: (2019)

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
por: Adashek, Jacob J., et al.
Publicado: (2019)

Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
por: Arnold, Peter, et al.
Publicado: (2021)

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice
por: Patel, Priyanka H., et al.
Publicado: (2022)

The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer
por: Papadopoulos, Efthymios, et al.
Publicado: (2023)

Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
por: Chi, Kim N, et al.
Publicado: (2023)

Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials
por: Schultz, Neil M., et al.
Publicado: (2018)

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer
por: Scholz, Mark, et al.
Publicado: (2017)

Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort
por: Rouyer, Magali, et al.
Publicado: (2019)

Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials
por: Armstrong, Andrew J., et al.
Publicado: (2019)

Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
por: Rathi, Nityam, et al.
Publicado: (2020)

Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression
por: Ruchalski, Kathleen, et al.
Publicado: (2022)

Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review
por: Meagher, Margaret F, et al.
Publicado: (2023)

A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research
por: Laccetti, Andrew L, et al.
Publicado: (2020)

Clinical Characterization of Mismatch Repair Gene-Deficient Metastatic Castration-Resistant Prostate Cancer
por: Ye, Senlin, et al.
Publicado: (2020)

Morphological and functional alterations of the prostate tissue during clinical progression in hormonally-naïve, hormonally-treated and castration-resistant patients with metastatic prostate cancer
por: Korček, Michal, et al.
Publicado: (2020)

Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer
por: Koo, Kyo Chul, et al.
Publicado: (2015)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials
por: Schultz, Neil M, et al.
Publicado: (2018)

Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer
por: Amato, Robert J., et al.
Publicado: (2012)

Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2020)

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
por: Mizokami, Atsushi, et al.
Publicado: (2017)

Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience
por: Poon, Darren M. C., et al.
Publicado: (2016)

Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
por: Prelaj, Arsela, et al.
Publicado: (2019)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Juzeniene, Asta, et al.
Publicado: (2021)

Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer
por: Mak, Blossom, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1rbpnt0es7jbqv802i8eils7te